HPV Vaccine Slashes Boys' Cancer Risk by Nearly Half, Major Study Finds
A groundbreaking new study published in JAMA Oncology reveals that boys who receive the HPV vaccine could reduce their risk of developing certain cancers by an impressive 46 per cent. The research, which analysed health records from more than three million young men, provides some of the strongest evidence yet that the vaccine offers significant cancer protection for males.
Significant Reduction in HPV-Related Cancers
The study focused specifically on males who received the latest version of the HPV vaccine, which protects against nine high-risk strains of the virus. Researchers found these vaccinated males were substantially less likely to develop a range of cancers linked to human papillomavirus, including cancers of the head, neck, and penis.
In practical terms, the risk dropped from approximately 12.5 cases per 100,000 in unvaccinated males to just 7.8 per 100,000 among those who had received the jab. This protective effect was consistent across both younger teenagers and young adults, demonstrating the vaccine's effectiveness across different age groups.
Addressing a Research Gap in Male Protection
Until now, most evidence demonstrating that the HPV vaccine prevents cancer has concentrated on women, particularly regarding cervical cancer. Previous research in men primarily examined whether vaccination reduced infection rates rather than whether it actually prevented cancer development.
This latest study directly compared vaccinated and unvaccinated males, making the findings more robust and providing clearer evidence that the vaccine can protect men from cancer. "The HPV vaccine is not just for girls and could play a key role in preventing cancer in men as well," the researchers concluded.
Current Vaccination Programmes and Recommendations
Despite these compelling findings, many countries still primarily offer HPV vaccination to girls. Scientists argue that expanding programmes to include boys could help reduce overall virus transmission, protect men directly, and accelerate the global decline in HPV-related cancers.
In the United Kingdom, the HPV vaccination programme has been extended since September 2019 to include all boys in Year 8 (aged 12 to 13), ensuring broader protection against HPV-related cancers after previously being offered only to girls. The vaccine is typically delivered through school-based programmes and targets high-risk HPV strains linked to cervical, genital, and head and neck cancers.
Additional Considerations and Future Research
The researchers noted several important caveats: cancer cases in young men remain relatively rare, and not all the cancers studied are exclusively caused by HPV. They also emphasised that longer follow-up over several decades will be necessary to fully understand the vaccine's long-term impact on cancer prevention.
Men who have sex with men aged up to 45 can also request the vaccine for free through sexual health and HIV clinics in the UK. Studies suggest this group may face a higher risk of anal cancer, and vaccination can help reduce that risk by protecting against HPV.
Understanding HPV and Cancer Risks
Human papillomavirus (HPV) is an extremely common virus spread through skin-to-skin contact. While often harmless, it can lead to serious diseases and is known to cause several cancers, including those affecting the head and neck, anus and penis, and cervical cancer in women.
Oral sex is considered a leading risk factor for HPV-related oropharyngeal cancer, a type of throat cancer, largely due to transmission of high-risk strains such as HPV-16. While many people contract oral HPV, most clear the infection naturally, but a small proportion develop persistent infections that can lead to cancer over time.
The study's findings underscore the importance of comprehensive HPV vaccination programmes that include both boys and girls to maximise protection against HPV-related cancers across the entire population.
